Results 81 to 90 of about 1,115 (163)

Thrombopoietin Receptor Agonists for Chemotherapy-Induced Thrombocytopenia: A Systematic Review and Network Meta-Analysis

Journal of Clinical Question
Background: Chemotherapy-induced thrombocytopenia (CIT) can lead to chemotherapy delays, dose reductions, and the need for platelet transfusions. However, comparative evidence for thrombopoietin receptor agonists (TPO-RAs) is limited.
Yong-Mei Guo, Yan Zhao, Toshiyoshi Maeda, Nouhaila Ezzaoui, Chinwebudu M. Melford   +4 more
doaj   +1 more source

Avatrombopag [PDF]

British Journal of Haematology, 2018
openaire   +2 more sources

Therapeutic options for adult patients with previously treated immune thrombocytopenia – a systematic review and network meta-analysis

, 2019
Objectives: The great majority of adult patients with immune thrombocytopenia (ITP) who fail to respond to first-line medication or who relapse following response require additional treatment. Although broad guidelines currently exist for second-line and
Ou Ji (6246059), Lin Lin (46073), Hao Yao (1539010), Ran Yang (519945), Qun Shen (2095693)   +4 more
core   +1 more source

Successful avatrombopag combined with cyclosporine treatment for carboplatin/pegylated liposomal doxorubicin/bevacizumab-induced acquired amegakaryocytic thrombocytopenia in a patient with recurrent ovarian cancer: case report

Frontiers in Oncology
Carboplatin/pegylated liposomal doxorubicin/bevacizumab is an accepted standard anti-cancer treatment option for recurrent ovarian cancer. However, the occurrence of adverse events associated with this therapeutic regimen limits its continued clinical ...
Weikang Meng, Jinsheng Hua, Jiabing Wang
doaj   +1 more source

Avatrombopag as alternative therapy for severe aplastic anemia patients who are intolerant or unresponsive to eltrombopag

Frontiers in Immunology
IntroductionEltrombopag (EPAG), a thrombopoietin receptor agonist, was approved for the treatment of severe aplastic anemia (SAA) combined with immunosuppressive therapy (IST).
Ting Zhang, Qingling Yu, Xiaoyu Chen, Hui Yang, Yuemin Gong, Yawen Zhang, Xiaoqing Liu, Zhinan Yang, Yu Fang, Xue Yan, Xuan Zhou, Jinning Shi, Guangsheng He   +12 more
doaj   +1 more source

Avatrombopag for the treatment of patients with chemotherapy-induced thrombocytopenia: A case series.

Management of chemotherapy-induced thrombocytopenia (CIT) is challenging, often resulting in chemotherapy treatment delays, dose reduction, and treatment interruption. Randomized trials support the potential efficacy and safety of thrombopoietin receptor
Johnston, Stephanie, Galamaga, Robert, Acosta, Cassaundra   +2 more
core   +1 more source

Should thrombopoietin receptor agonists be used for chemotherapy-induced thrombocytopenia?

Research and Practice in Thrombosis and Haemostasis
Chemotherapy-induced thrombocytopenia (CIT) is a common complication of cancer therapy for solid tumors that results in increased bleeding risk and chemotherapy dose reductions, treatment delays, and agent discontinuation.
Hanny Al-Samkari
doaj   +1 more source

Response to avatrombopag among patients with chronic and acute or persistent primary immune thrombocytopenia: REAL-AVA 2.0 real-world study

Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by low platelet counts (PCs) and increased bleeding risk.Thrombopoietin receptor agonists (TPO-RA) aim to increase PCs to target levels to minimize this risk.
Shruti Chaturvedi, Elyse Swallow, Alexandra Greatsinger, Abiola Oladapo, Sinia Sareen, Chelsea Bernheisel, Michael Vredenburg, Srikanth Nagalla, Debbie Goldschmidt, Loren Ormenaj, M Y Levy, Scott Kolodny   +11 more
core   +1 more source

Efficacy of avatrombopag in patients with immune thrombocytopenia

Oncohematology
Background. Thrombopoietin receptor agonists are considered second-line therapy and are prescribed to patients with insufficient response or intolerance to first-line therapy. These drugs, which stimulate platelet production by activating the thrombopoietin receptor, are effective and safe for both short-term and long-term treatment of immune ...
Sergey G. Zakharov, T. A. Mitina, A. V. Zakharova, N. A. Demakova, Yu. B. Chernykh, K. A. Belousov, L. L. Vysotskaya, E. V. Trifonova   +7 more
openaire   +1 more source

Real-life experience with avatrombopag

Digestive Medicine Research, 2021
Dhruv Verma, Jung J. Yum, Kyra LeRoy, Terina K. McDaniel, Sammy Saab   +4 more
openaire   +1 more source